Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 122,248 shares at $64.80 ($8.1M) on 2024-03-11, disclosed to the SEC on 2024-03-11.
Scheduled sale ($8.1M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.38 | 31,958 | $2.1M | 26.3% |
| 2 | $66.38 | 31,958 | $2.1M | 26.3% |
| 3 | $66.93 | 8,754 | $586K | 7.3% |
| 4 | $66.93 | 8,754 | $586K | 7.3% |
| 5 | $64.80 | 14,541 | $942K | 11.7% |
| 6 | $64.80 | 14,541 |
| $942K |
| 11.7% |
| 7 | $65.90 | 4,128 | $272K | 3.4% |
| 8 | $65.90 | 4,128 | $272K | 3.4% |
| 9 | $66.81 | 1,590 | $106K | 1.3% |
| 10 | $66.81 | 1,590 | $106K | 1.3% |
| 11 | $67.33 | 306 | $21K | 0.3% |
| Total | $66.06 avg | 122,248 | $8.1M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-02-27 | $3.1M | — | Filing → |